Search

Rhythm Pharmaceuticals Inc

Closed

SectorHealthcare

114.92 -0.15

Overview

Share price change

24h

Current

Min

114.92

Max

116.14

Key metrics

By Trading Economics

Income

-49M

-105M

Sales

11M

71M

EPS

-0.73

Profit margin

-147.27

Employees

414

EBITDA

5.9M

-44M

Recommendations

By TipRanks

Recommendations

Strong Buy

12 Months Forecast

+23.37% upside

Dividends

By Acuity

Next Earnings

3 Nov 2026

Market Stats

By TradingEconomics

Market Cap

901M

8B

Previous open

115.07

Previous close

114.92

News Sentiment

By Acuity

54%

46%

279 / 340 Healthcare

Rhythm Pharmaceuticals Inc Chart

Past performance is not a reliable indicator of future results.

Related News

13 Aug 2026, 19:51 UTC

Rhythm Pharmaceuticals is advancing amid broader market gains, supported by strong technology sector performance and high trading volume, despite no specific company news.

12 Aug 2026, 19:46 UTC

Event

Rhythm Pharmaceuticals received expanded marketing authorization for IMCIVREE in the UK. Shares are trading higher since Tuesday's close, near the upper end of their one-month range.

11 Aug 2026, 19:36 UTC

Social Media
News
Event

Rhythm Pharmaceuticals received expanded UK approval for IMCIVREE to treat obesity, yet shares are declining amid broader market sentiment concerns.

10 Aug 2026, 19:31 UTC

Rhythm Pharmaceuticals Inc shares are lower today, retracing gains after an early drop. The stock is experiencing unusually high trading volume.

7 Aug 2026, 20:06 UTC

News

RYTM higher after JPMorgan raised price target to $146.00.

6 Aug 2026, 21:05 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reaching a high and remaining above the 20-day moving average. No specific news was identified.

5 Aug 2026, 20:02 UTC

Event
News

Rhythm Pharmaceuticals shares rise as Citigroup, RBC, and Citizens raise price targets to $143, $155, and $160, respectively, reflecting growing confidence in the company.

4 Aug 2026, 20:13 UTC

News

Rhythm Pharmaceuticals shares are trading higher in after-market hours following CEO and CFO participation in upcoming investor conferences, enhancing visibility among stakeholders.

3 Aug 2026, 19:51 UTC

Rhythm Pharmaceuticals Inc shares are higher today amid unusually high trading volume, continuing the upward trend since Friday's close. No specific news was identified.

31 Jul 2026, 22:56 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, despite earlier fluctuations and no specific news identified to explain the movement.

30 Jul 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, continuing a downward trend since Wednesday. No specific news has been identified to explain the decline.

29 Jul 2026, 18:46 UTC

Rhythm Pharmaceuticals Inc shares are lower today, influenced by rising oil prices amid escalating Middle East tensions, though no specific company news was identified.

28 Jul 2026, 19:11 UTC

Rhythm Pharmaceuticals Inc. shares are higher today, supported by strong trading volume and positive momentum in the biotechnology sector. No specific news was identified.

27 Jul 2026, 19:33 UTC

News

RYTM trades higher after JPMorgan's Overweight rating and $145 target.

24 Jul 2026, 21:01 UTC

Rhythm Pharmaceuticals Inc shares are higher in after-market trading, reflecting a positive shift since Friday's close despite broader market challenges.

21 Jul 2026, 14:36 UTC

News

Rhythm Pharmaceuticals will report second-quarter 2026 results on August 4, contributing to higher shares amid positive market sentiment and gains in the Nasdaq 100 Index.

20 Jul 2026, 20:51 UTC

Rhythm Pharmaceuticals Inc is lower in after-market trading, down significantly from Monday's close and below its 20-day moving average. No specific news was identified.

Peer Comparison

Price change

Rhythm Pharmaceuticals Inc Forecast

Price Target

By TipRanks

23.37% upside

12 Months Forecast

Average 142.47 USD  23.37%

High 160 USD

Low 105 USD

Based on 15 Wall Street analysts offering 12 month price targets forRhythm Pharmaceuticals Inc - Dist in the last 3 months.

Rating Consensus

By TipRanks

Strong Buy

15 ratings

15

Buy

0

Hold

0

Sell

Sentiment

By Acuity

279 / 340 Healthcare

News Sentiment

Bearish Evidence

Volatility

Below average

News Volume (RCV)

Below average

Financials

Selling and administration expenses

Operating expenses

Pre-tax profit

Sales

Cost of sales

Gross profit on sales

Interest expense on debt

EBITDA

Operating profit

$

About Rhythm Pharmaceuticals Inc

Rhythm Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the rare neuroendocrine diseases. The company's lead product candidate is IMCIVREE (setmelanotide), a rare melanocortin-4 receptor for the treatment of pro-opiomelanocortin (POMC), proprotein convertase subtilisin/kexin type 1, leptin receptor (LEPR) deficiency obesity, and Bardet-Biedl and Alström syndrome. It is in Phase 3 clinical trials for treating POMC or LEPR heterozygous deficiency obesities, steroid receptor coactivator 1 deficiency obesity, SH2B1 deficiency obesity, MC4 receptor deficiency obesity, and other MC4R disorders. The company has licensing agreements with LG Chem, Ltd; Ipsen Pharma S.A.S; Camurus; RareStone Group Ltd.; joint research collaboration with Axovia Therapeutics for developing in bardet-biedl syndrome; and LG Chem, Ltd. The company was formerly known as Rhythm Metabolic, Inc. and changed its name to Rhythm Pharmaceuticals, Inc. in October 2015. Rhythm Pharmaceuticals, Inc. was founded in 2008 and is headquartered in Boston, Massachusetts.
help-icon Live chat